MULTIMODAL IMAGING IN DEFEROXAMINE-RELATED OCULAR TOXICITY: RAPID DEVELOPMENT DUE TO SUPRATHERPEUTIC DOSING AND PROGRESSION DESPITE DOSE REDUCTION.

Q3 Medicine

Retinal Cases and Brief Reports Pub Date : 2025-03-03 DOI:10.1097/ICB.0000000000001746

Elisah M Huynh, Mahmood Khan, Yanhan Ren, Anton Orlin, Szilard Kiss, Benjamin W Botsford

{"title":"MULTIMODAL IMAGING IN DEFEROXAMINE-RELATED OCULAR TOXICITY: RAPID DEVELOPMENT DUE TO SUPRATHERPEUTIC DOSING AND PROGRESSION DESPITE DOSE REDUCTION.","authors":"Elisah M Huynh, Mahmood Khan, Yanhan Ren, Anton Orlin, Szilard Kiss, Benjamin W Botsford","doi":"10.1097/ICB.0000000000001746","DOIUrl":null,"url":null,"abstract":"Purpose: To characterize evolution of deferoxamine-related retinal toxicity in a patient exposed to supratherapeutic doses of deferoxamine and progression despite dose reduction and cessation.Methods: Observational clinical case Report.Results: A 59-year-old female with history of beta thalassemia requiring biweekly blood transfusions developed peripheral visual field loss and nyctalopia after taking supratherapeutic dosage of deferoxamine. She demonstrated progressive RPE thickening and photoreceptor loss despite reduction in dosage as she was unable to initially discontinue the medication, as vision decreased from 20/25 and 20/30 to 20/60 and 20/50. This report highlights the ocular toxicities linked with deferoxamine and examines whether dosage decrease reverses its effects.Conclusion: Deferoxamine use can precipitate RPE changes, thickening, and photoreceptor loss that can progress despite dose-reduction and cessation.","PeriodicalId":53580,"journal":{"name":"Retinal Cases and Brief Reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retinal Cases and Brief Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ICB.0000000000001746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To characterize evolution of deferoxamine-related retinal toxicity in a patient exposed to supratherapeutic doses of deferoxamine and progression despite dose reduction and cessation.

Methods: Observational clinical case Report.

Results: A 59-year-old female with history of beta thalassemia requiring biweekly blood transfusions developed peripheral visual field loss and nyctalopia after taking supratherapeutic dosage of deferoxamine. She demonstrated progressive RPE thickening and photoreceptor loss despite reduction in dosage as she was unable to initially discontinue the medication, as vision decreased from 20/25 and 20/30 to 20/60 and 20/50. This report highlights the ocular toxicities linked with deferoxamine and examines whether dosage decrease reverses its effects.

Conclusion: Deferoxamine use can precipitate RPE changes, thickening, and photoreceptor loss that can progress despite dose-reduction and cessation.

查看原文本刊更多论文

多模态成像在去铁胺相关的眼部毒性：由于超治疗剂量的快速发展和尽管剂量减少进展。

目的：描述暴露于超治疗剂量去铁胺的患者的去铁胺相关视网膜毒性的演变和进展，尽管剂量减少和停止。方法：观察性临床病例报告。结果：一名59岁女性，有地中海贫血病史，需要每两周输血，服用超治疗剂量的去铁胺后出现周围视野丧失和夜盲症。尽管剂量减少，但由于患者最初无法停药，视力从20/25和20/30下降到20/60和20/50，患者表现出进行性RPE增厚和光感受器丧失。本报告强调了与去铁胺相关的眼部毒性，并研究了减少剂量是否会逆转其作用。结论：去铁胺的使用可导致RPE改变、增厚和光感受器丧失，尽管减少剂量和停止使用，这些变化仍会继续。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊